Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as 18F-mFBG for intravenous administration
18F-mFBG for administration · 1 trial · 1 indication
Change in 18F-mFBG uptake in the total body and the normal heart over time (based on serial PET images) to: * document the time course of global and regional myocardial activity reflecting specific uptake and clearance of the radiopharmaceutical; * estimate individual organ and whole-body radiation dosimetry.
To demonstrate the extent and degree of global and regional reduced 18F-mFBG myocardial uptake on PET/CT (or PET/MR) of HF subjects with significant LV dysfunction (LVEF≤35%).
| Arm | Type | Description |
|---|---|---|
| Low likelihood of coronary heart disease | OTHER | Thorax and total body imaging for quantification of normal biodistribution and myocardial sympathetic innervation. PET imaging to 210 minutes post-administration. |
| Heart Failure + left ventricular function (LVEF ≤ 35%) | OTHER | Thorax and total body imaging for quantification of myocardial sympathetic innervation. PET imaging to 100 minutes post-administration |
| Name | Type | Description |
|---|---|---|
| 18F-mFBG for intravenous administration | DRUG | Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent |
Inclusion Criteria: * ≥ 18 years of age at study entry * able and willing to comply with study procedures * signed and dated informed consent is obtained * male or a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or hysterectomy), postmenopausal (cessation ...
Top 4 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Eli Lilly and Company | LLY | 1 | PHASE3 | Lepodisiran |
| Illumina, Inc. | ILMN | 1 | PHASE1 | 18F-mFBG for administration |
18F-mFBG for administration is an investigational small molecule imaging agent being studied in cardiovascular disease. It is a PET imaging agent designed to visualize myocardial sympathetic innervation, the nerve supply to the heart muscle. It is in Phase 1 clinical development and is not approved for commercial use.
18F-mFBG for administration is being studied for imaging myocardial sympathetic innervation in patients with cardiovascular diseases. The single Phase 1 trial, NCT04535193, is an open-label study evaluating its use as a PET imaging agent to visualize the sympathetic nerve supply to the heart.
18F-mFBG for administration is being developed by Illumina, Inc., which trades under the ticker ILMN. The company is sponsoring the Phase 1 clinical program evaluating this imaging agent in cardiovascular disease.
18F-mFBG for administration is in Phase 1 clinical development. It is investigational and has not been approved by the FDA. The program includes one active trial that is currently not recruiting participants.
18F-mFBG for administration is being studied in one clinical trial, NCT04535193, titled "Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation." This Phase 1 trial is active but not recruiting, has enrolled 10 participants, and is being conducted in the United States.
Yes, 18F-mFBG for intravenous administration is an alternative name for 18F-mFBG for administration. Both refer to the same investigational PET imaging agent being developed by Illumina, Inc. for imaging myocardial sympathetic innervation in cardiovascular disease.